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Abstract A crude fraction that contains ubiquitin-protein 
ligases contains also a proteolytic activity of ~100 kDa that 
cleaves p53 to several fragments. The protease does not require 
ATP and is inhibited in the crude extract by an endogenous 
~250 kDa inhibitor. The proteinase can be inhibited by 
chelating the Ca2+ ions, by specific cysteine proteinase inhibitors 
and by peptide aldehyde derivatives that inhibit calpains. Purified 
calpain demonstrates an identical activity that can be inhibited 
by calpastatin, the specific protein inhibitor of the enzyme. Thus, 
it appears that the activity we have identified in the extract is 
catalyzed by calpain. The calpain in the extract degrades also N-
myc, c-Fos and c-Jun, but not lysozyme. In crude extract, the 
calpain activity can be demonstrated only when the molar ratio of 
the calpain exceeds that of its native inhibitor. Recent 
experimental evidence implicates both the ubiquitin proteasome 
pathway and calpain in the degradation of the tumor suppressor, 
and it was proposed that the two pathways may play a role in 
targeting the protein under various conditions. The potential role 
of the two systems in this important metabolic process is 
discussed. 
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1. Introduction 
Accumulating evidence suggests that the ubiquitin-protea-
some pathway plays a major role in the degradation of p53 
and other transcriptional activators. Recent evidence suggests 
that these proteins are also degraded by calpains, at least 
under certain conditions. It is therefore important to deter-
mine the role of the two proteolytic systems in these central 
metabolic processes. 
The ubiquitin pathway plays an important role in the deg-
radation of many short-lived regulatory proteins. Degradation 
of a protein via the system involves two successive steps, con-
jugation of multiple molecules of ubiquitin to the target pro-
tein and degradation of the tagged molecule by the 26S pro-
teasome (reviewed in [1] and [2]). In vivo, Gronostajski and 
colleagues demonstrated that the degradation of p53 in cells 
requires ATP, a characteristic that is a hallmark in the activity 
of the ubiquitin system [3]. Chowdary and colleagues have 
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shown that inactivation of El, the first enzyme in the ubiq-
uitin pathway, results in accumulation of the tumor suppres-
sor [4]. Maki and colleagues showed that in the presence of 
lactacystin, a specific inhibitor of the 20S proteasome, p53 
stabilizes, a process that is accompanied by accumulation of 
the intermediates p53-ubiquitin adducts [5]. These findings 
demonstrate that p53 serves as a direct substrate of the ubiq-
uitin system. In contrast, calpain inhibitor II that is a weak 
inhibitor of the proteasome, did not affect the fate of p53. It 
should be noted that in all these studies where the ubiquitin 
system was inhibited, researchers could not identify proteo-
lytic intermediate products that could have suggested that the 
system plays a secondary role in a process where the initial 
cleavage/marking is carried out by a different system. In vitro, 
immunodepletion of El leads to inhibition of degradation of 
p53 [6]. Utilizing both intact cells and a cell-free system, 
Scheffher and colleagues found that HPV oncoprotein E6 
transforms cells, at least partially, by targeting p53 for degra-
dation via the ubiquitin system [7,8]. 
Calpains are calcium-dependent cysteine proteinases present 
in a variety of cells (reviewed in [9] and [10]). Some of the 
enzymes are distributed ubiquitously, while others are tissue-
specific. Most of the current knowledge about the enzymolog-
ical and biological properties of calpains applies to the ubiq-
uitous isozymes u-calpain and macrocalpain that differ in the 
optimal Ca2+ concentration in which they are active (u.M vs. 
mM concentrations, respectively). They localize mainly in cy-
toplasm. All the calpains characterized are heterodimers con-
sisting of a large and a small subunit. The large subunit has a 
catalytic and regulatory domains whereas the small subunit, 
that is common to both isozymes, carries another regulatory 
calcium binding domain. The nature of calpain-catalyzed pro-
teolysis is not digestive: rather, it proceeds in a limited man-
ner and results in several cleavages. All cells that contain 
calpains, contain also specific protein inhibitors of these en-
zymes, calpastatins. In many cells, the inhibitor concentration 
exceeds that of the enzyme and is sufficient to block all Ca2+-
dependent proteolysis in unfractionated extracts. Conse-
quently, a major unresolved problem involves the identity 
the physiological substrates of these enzymes. It has been 
reported that following activation, calpains are translocated 
to the cell membrane and are sequestered from their inhibi-
tors. Therefore, many potential substrates of calpains are 
membrane or membrane-associated proteins such as growth 
factor receptors, adhesion molecules, cytoskeletal and micro-
tubule-associated proteins. In this context it is important to 
mention that mutations in the muscle specific calpain 3 en-
zyme lead to limb-girdle muscle dystrophy [11]. A recent study 
has implicated calpains in the degradation of p53 [12]. The 
researchers have shown that in certain cell extracts, calpain is 
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probably in excess over its protein inhibitor and the suppres-
sor can be cleaved in unfractionated lysate. Such exceptional 
cases have been also described, for example, in rat erythro-
cytes [13] and during the maturation and fusion of myoblasts 
[14]. To demonstrate the involvement of the proteinase in p53 
degradation, the researchers used also calpain inhibitors that 
inhibit, although less efficiently, the 20S proteasome. As for 
other potential protein substrates of calpains, Hirai and col-
leagues and Carillo and colleagues reported that calpains may 
be involved in the degradation of c-Fos and c-Jun in vitro 
[15,16]. Stancovski and colleagues reported however that c-
Fos is targeted by the ubiquitin system both in vivo and in 
vitro [17]. Liu and colleagues reported that the transcription 
factor inhibitor IKBOC can be targeted by calpains in vitro [18]. 
It should be noted that here also researchers have shown that 
the ubiquitin system is involved in the process both in vivo 
and in vitro [19,20]. Furthermore, in this case the specific 
ubiquitin system-targeting signal has been identified and mu-
tations in this signal lead to stabilization of the protein. 
2. Materials and methods 
2.1. Materials 
Hiload Superdex 200HR (16x600 mm) column was from Pharma-
cia. Materials for SDS-PAGE were from Bio-Rad. Centricons and 
Centripreps were from Amicon. Most fine chemicals and proteinase 
inhibitors were purchased from Sigma. MG115, a 20S proteasome and 
calpain inhibitor, was a kind gift from Drs. J. Adams and R. Stein, 
ProScript Inc., Cambridge, MA. Purified calpain and calpastatin were 
prepared from human erythrocytes as described [13,14] or purchased 
from Sigma. Radioactive materials were from DuPont NEN. All oth-
er Chemicals were of high analytical grade. 
2.2. Methods 
2.2.1. Preparation of the labeled substrates. cDNAs for p53, c-Fos, 
and human N-myc in pSP65 vector have been described elsewhere 
[6,17]. The pKH6 vector containing human c-Jun was a generous 
gift from Dr. Dirk Bohmann (EMBL, Heidelberg, Germany). 35S-
methionine-labeled substrates were generated in vitro in a coupled 
transcription-translation reaction in wheat germ extract (TNT, Prom-
ega) and partially purified as described [6,21]. 125I-labeled lysozyme 
was prepared by the chloramine T method as described [22]. 
2.2.2. Partial purification of the p53-cleaving proteinase. Rabbit 
reticulocyte lysates were prepared and resolved by anion exchange 
chromatography on DEAE cellulose into unadsorbed material (frac-
tion I) and high salt eluate (fraction II) as described [21,22]. Frac-
tion II was fractionated by (NH4)2S04 into fraction IIA (0-38%) 
[22]. Two milliliters of fraction IIA (20 mg/ml) were loaded onto a 
HiLoad Superdex 200 HR (16x600 mm) gel filtration chromatogra-
phy column, and the proteins were resolved in a buffer containing 20 
mM Tris-HCl, pH 7.2, 150 mM NaCl, and 2 mM DTT (buffer A), 
using an FPLC system (Pharmacia). Fractions (2.4 ml) were collected, 
and salt was removed by repeated concentration-dilution cycles using 
Centricon 30 microconcentrators with buffer A without NaCl. Frac-
tions were finally concentrated to ~ 100 ul. 
2.2.3. Determination of the p53-cleaving proteinase activity. Degra-
dation of 35S-methionine-labeled substrates and 125I-labeled lysozyme 
was performed in a reaction mixture containing in a final volume of 
25 ill: partially purified proteinase (fraction 31 or pooled fractions 31 
and 32 from the Superdex 200 column as described above and in the 
legend to Fig. 1), 40 mM Tris-HCl, pH 7.6, 1 mM DTT, 1 mM CaCl2, 
and the labeled substrate. Mixtures were incubated for 30 min at 
30°C. Following incubation, reaction mixtures were resolved via 
SDS-PAGE and proteins were visualized either following fluorogra-
phy and exposure to film or by using a Phosphorlmager (Fuji, Japan). 
When the activity of different inhibitors was studied, they were pre-
incubated for 5 min at 30°C in the presence of the proteinase prior to 
the addition of the substrates. 
2.2.4. Conjugation assay. E6-dependent conjugation of ubiquitin 
to 35S-labeled p53 in the presence of purified El, E2 and a partially 
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purified preparation of E3 (aliquots from the resolved fraction IIA; 
see above) was monitored as described [17,21]. 
3. Results 
3.1. Gel filtration chromatography of fraction IIA reveals a 
proteinase that cleaves p53 
In our efforts to resolve E6-AP, the E3 enzyme that is in-
volved in E6-dependent degradation of p53, from the E3 that 
is involved in degradation of p53 in the absence of the HPV 
oncoprotein, we fractionated via gel filtration chromatogra-
phy crude rabbit reticulocyte fraction IIA that contains all 
the known species of E3 enzymes [21,23]. Aliquots from the 
column fractions were assayed for formation of ubiquitin-p53 
conjugates in the presence of purified El and E2 enzymes. 
Surprisingly, in a molecular mass region of ~ 100 kDa, we 
noted a strong proteolytic activity that degraded p53 to a 
limited extent (Fig. 1, fractions 30-32). The activity does 
not require ATP as the conjugation assay was carried out in 
the presence of the non-cleavable analog, ATP-y-S. To rule 
the possibility that the proteinase utilizes the available a-(3 
high energy phosphate bond, we carried out the assay in the 
absence of ATP-y-S. The proteinase can cleave p53 in an en-
ergy-independent manner (not shown). Obviously, the process 
does not require also the other two conjugating enzymes, El 
and E2, that were present in the assay presented in Fig. 1 (not 
shown), and appears to be carried out by a unique proteinase. 
3.2. Identification of a specific inhibitor of the p53-cleaving 
proteinase 
The absence of the proteolytic activity from the crude ex-
tract (Fig. 1) and whole lysate [6] lead us to test the hypothesis 
that the activity is masked by a specific inhibitor. As can be 
seen in Fig. 2, the proteinase activity in fraction 31 can be 
inhibited by adding crude fraction II that contains, most 
probably, the inhibitor. In order to identify the inhibitor 
more precisely, we examined the different column fractions 
in the presence of the active proteinase. As can be seen in 
Fig. 2, fractions 21-27 (a peak at fraction 25 with a MW of 
~ 250 kDa) contain an inhibitor of the cleaving activity. 
3.3. Characterization of the p53 proteinase 
To further characterize the proteinase, we tested the effect 
of pH and a selected group of inhibitors. The cleaving enzyme 
is a neutral proteinase that has an optimal activity at pH 7.6. 
At acidic and basic region pHs, the enzyme is inactive (not 
shown). As can be seen in Fig. 3, the Ca2+ chelators EDTA 
and EGTA strongly inhibit the enzyme. In addition, the cys-
teine proteinase inhibitors, leupeptin and E64, and the -SH 
alkylating agent NEM, also inhibit the enzyme. The calpain 
inhibitors ALLN and ALLM, and the proteasome inhibitor 
MG115 that inhibits also calpains [24], inhibit the enzyme as 
well. In contrast, the serine proteinase inhibitors PMSF, 
TPCK, TLCK, and STI, the aspartic proteinase inhibitor pep-
statin A, and the Fe2+ chelator ophenanthroline, did not 
have any effect. From the inhibitors profile it appears that 
the p53-cleaving activity is calpain. Kinetic measurements 
showed that the proteolysis of p53 is rapid: in 2 min almost 
all the substrate has been cleaved to high molecular weight 
intermediates, whereas after 20 min the degradation was com-
plete (not shown). 
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Fig. 1. Gel filtration chromatography of crude fraction IIA reveals a p53-cleaving activity. Ubiquitin-p53 conjugates were generated in the pres-
ence of El, E2, the human papiUomavirus oncoprotein E6 and 2 ul aliquots from the gel filtration-resolved fraction IIA as described under 
Section 2. Numbers denote fraction numbers. —Ext., reaction mixture incubated in the presence of all the components except for the ligase; 
FrII, a similar reaction incubated in the presence of crude fraction IIA prior to chromatography; V0, void volume of the column; E6-AP, 
point of elution of E6-associated protein; Pr., p53-cleaving proteinase; p53, labeled substrate; Conj., p53-ubiquitin conjugates; Ori., origin. 
Gel filtration chromatography MW markers are: 669.0, thyroglobulin; 443.0, apoferritin; 159.0, aldolase; 68.0, bovine serum albumin. SDS-
PAGE MW markers are: 200.0, myosin; 116.0, (3-galactosidase; 97.6, phosphorylase b; 68.0, bovine serum albumin; 46.0, ovalbumin; 30.0, 
carbonic anhydrase. 
3.4. The p53-cleaving enzyme is calpain 
To test directly the notion that the p53-cleaving enzyme is 
calpain and that the inhibitor is calpastatin, we tested the 
effect of different calpain and calpastatin preparations on 
the proteolysis of p53. As can be seen in Fig. 4, all three 
preparations tested, the enzyme contained in fraction 31, a 
purified commercial calpain, and an homogeneously purified 
calpain from human erythrocytes, displayed an identical pro-
teolytic profile. Furthermore, all three different inhibitor prep-
arations, the one isolated from fraction IIA, commercially 
available calpastatin, and purified calpastatin from human 
erythrocytes, inhibit the three enzymes to the same extent. 
Thus, it is apparent that the p53-cleaving activity from frac-
tion IIA is indeed calpain. It should be noted that similar to 
the activities in the crude extract, the molecular mass of cal-
pain is 110 kDa whereas calpastatin is a multimeric inhibitor 
that appears frequently as a ~250 kDa complex [13]. 
3.5. Additional substrates of the p53-cleaving proteinase 
To examine the substrate specificity of the calpain, we 
tested the activity in fraction 31 towards human N-myc, c-
Fos, c-Jun and lysozyme. As can be seen in Fig. 5, myc, 
Fos and Jun were all proteolyzed by the enzyme. Calpastatin 
inhibits the degradation of all these proteins. Like p53, deg-
radation of c-Fos yields intermediate products whereas the 
degradation of c-Jun and N-myc proceeds to completion. In-
Fr.II 
Fr.31 
S-200 Fr. 
I>53 —» 
kDn 49.5 -
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p53 
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D.F.- D.F. 
Fig. 2. Fraction IIA contains an inhibitor of the p53-cleaving activity. Aliquots (2 ul) of the different fractions (marked in numbers; see legend 
to Fig. 1) were assayed for the inhibitor of the p53-cleaving proteinase. Reaction mixtures contained also 2 jj.1 aliquots of fraction 31 as a 
source of the proteinase. Proteolysis of 35S-labeled p53 was monitored as described under Section 2. FrII, 1 ul aliquot of unresolved frac-
tion IIA that was added as a source of the inhibitor. Molecular mass markers (stained) are: 49.5, ovalbumin; 32.5, carbonic anhydrse; 27.5, 
STI; D.F., density dye front. All other notes are as described in the legend to Fig. 1. 
20 
\ +. +\\\\\ %% 
Fig. 3. Inhibitors of the p53-cleaving proteinase. Aliquots (2 ul) from pooled fractions 31 and 32 (used as a source of the proteinase) were as-
sayed for p53-cleaving activity as described under Section 2 in the absence and presence of the indicated inhibitors. Sub., reaction mixture incu-
bated in the presence of the labeled substrate alone; Pr., reaction mixture incubated in the presence of the proteinase. The concentration of the 
various proteinase inhibitors are: PMSF, 1 mM; TPCK, 1 mM; TLCK, 0.5 mM; EDTA, 2 mM; leupeptin, 1 ug/ml; E64, 10 ug/ml; NEM, 
5 mM; MG115, 100 uM; EGTA, 2 mM; ALLM, 7 ug/ml; ALLN, 17 ug/ml; pepstatin, 1 uM; STI, 10 ug/ml; o-phenanthroline, 1 mM. Other 
notes and molecular mass markers are as in the legends to Figs. 1 and 2 
terestingly, lysozyme that is proteolyzed efficiently by the 
ubiquitin system, was not degraded by calpain. Thus, the 
calpain has a broad specificity, at least in vitro, and it is not 
specific to p53. 
3.6. The ratio between calpain and calpastatin determines the 
activity of the enzyme in crude extracts 
It appears that in most cases, the activity of calpains in 
crude extracts is masked by excess of calpastatin, and only 
dissociation and separation of the two leads to expression of 
the activity. One such exception is the rat erythrocyte in which 
a calpain-dependent cell fusion activity could be demonstrated 
following addition of the membrane mobility agent A2C [13]. 
In contrast, such activity could not be demonstrated in human 
erythrocytes. Indeed, as can be seen in Fig. 6, crude rat eryth-
rocyte fraction IIA cleaves p53, whereas human fraction IIA 
was inactive. The activity in the rat extract could be inhibited 
by calpastatin. 
4. Discussion 
We have shown that calpain can cleave p53 in a cell-free 
system, and that the proteolytic activity is inhibited by the 
Inhibitor — — — — -^ -4? 
Protease - -fa + b + C + a +* 
p 5 3 - » 
46.0 — 
30.0 — 
Fig. 4. The p53-cleaving proteinase is calpain. The partially purified proteinase" (Superdex 200 fraction 31; 2 ul aliquot), a commercial prepara-
tion of calcium-activated neutral proteinaseb (0.05 U), and human erythrocytes purified calpain0 (0.025 U; [13]) were assayed for p53-cleaving 
activity as described under Section 2. The fraction IIA-resolved inhibitor1 (2 ul aliquot from fraction 25; see legend to Fig. 2), the commercial 
preparation of calpastatin2 (0.15 U), and calpastatin purified from human erythrocytes3 (0.075 U; [13]) were added as indicated. All other notes 
and molecular mass markers are as in the legend to Fig. 1. 
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endogenous native inhibitor of the enzyme, calpastatin. Since 
recent experimental evidence implicates both the ubiquitin 
system and calpains in the degradation of p53, we felt that 
it is important to review the data critically and to examine the 
possibility that the two systems cooperate in targeting the 
tumor suppressor protein for degradation. 
In dissecting the potential role of the two systems, one can 
think of several distinct mechanisms. One obvious possibility 
is that calpains carry out the initial limited cleavages, whereas 
the ubiquitin system operates downstream and is involved in 
the terminal degradation of the intermediate products. Several 
strong experimental lines of evidence suggest that this order of 
events is unlikely. First, p53 is stabilized in the absence of 
energy without concomitant accumulation of intermediate 
products [3]. While both activation of ubiquitin and the ac-
tivity of the 26S proteasome require energy in intact cells and 
in the cell-free system, activity of calpains appears to be en-
ergy-independent : calpains cleave proteins in crude extracts in 
the absence of ATP. It is still possible, although never been 
shown, that in the intact cell, energy is required also for cal-
pain activity. For example, ATP may be required in order to 
translocate the enzyme to its site of action. Another experi-
ment that suggests a role for the ubiquitin system in the initial 
4 +1 +2 +3 +1 +2 +3 
+ a + b + b + b + c + c + c 
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Fig. 5. Effect of calpain on proteolysis of human N-myc, c-Fos, c-Jun and lysozyme. Aliquot (2 ul) of fraction 31 were assayed for cleavage of 
p53 (A), human N-myc (B), c-Fos (C), c-Jun (D), and lysozyme (E) as described under Section 2. The inhibitor (2 u.1, fraction 25, Fig. 2) was 
added when indicated. MW markers and notes are as described in the legends to Figs. 1 and 2. 
proteolytic process and not downstream to calpains is stabili-
zation of the suppressor following inactivation of E l , the first 
enzyme in the ubiquitin pathway cascade [4]. However, here 
too one may argue that E l is not required directly for the 
ubiquitination of p53, but rather for activation of calpain in a 
yet unknown mechanism. However, there is no experimental 
evidence for such activation mechanism. Also, it should be 
noted that p53 has been shown to be a direct substrate of 
the ubiquitin system in vivo [5]. A second and distinct alter-
native is that the ubiquitin system is involved in the initial 
proteolytic event, whereas calpains act downstream. Here, 
the proteasome that acts as the proteolytic arm of the ubiq-
uitin system is required for the initial cleavage event. Mecha-
nistic dissection of the 20S proteasome reveals that the active 
sites in the (3 rings reside in a distance that allows, at the most, 
release of short peptides of ~ 8 amino acid residues [25]. 
Thus, the release of larger fragments will be difficult to ex-
plain. In one case however, processing of the p l 0 5 precursor 
of the N F - K B transcriptional activator, the proteasome is in-
volved in limited proteolysis and not in complete degradation 
of its target protein substrate. In this exceptional case of a 
single and specific cleavage site, a glycine-rich region appears 
to inhibit translocation of the molecule into the proteasomal 
pore [26], and a single processing product is released. To 
further substantiate the downstream function of calpains it 
will be necessary to utilize specific inhibitors of these enzymes 
that do not inhibit the activity of the proteasome and to show 
accumulation of intermediate products that were generated by 
the proteasome. A third possibility is that p53 is targeted by 
different mechanisms in different cells. To demonstrate that 
the process is mediated by calpains, it will be necessary to 
show that the enzyme concentration exceeds that of its inhib-
itor or that the two components are localized to different cell 
compartments . In several cells and occasionally under differ-
ent conditions, the molar ratio between the enzyme and the 
inhibitor changes and the enzyme can exist in its free form. 
For example, in maturing myoblasts, researchers noted a tran-
sient decrease in the level of calpastatin that leads, most prob-
ably, to activation of calpain and subsequent cell fusion that 
is an essential step in muscle development [14]. In the MCF-7 
cell line where degradation of p53 could be demonstrated in 
the crude extract, calpain concentration probably also exceeds 
that of calpastatin [12], al though it has not been shown di-
rectly. This is the case also in rat erythrocytes (see Section 3 
and Fig. 6). To demonstrate a primary role for calpains in the 
degradation of p53 in these exceptional cases, it will be neces-
sary to demonstrate that the process does not require energy 
and is not inhibited by specific proteasome inhibitors such as 
lactacystin. This has not been shown in a recent study in 
which calpains have been implicated in the basal, E6-inde-
pendent degradation of p53 [12]. A fourth and distinct alter-
Protein (Hg) 
calpastatin 
purified calpain 
hum. erythrocyte rat erythrocyte 
Fr. II Fr. II 
■ 15 45 15 45" l5 45 15 45 ' 
- - - + + " - + + 
p53-
kDa 
30.0 — 
14.3 — 
D.F.— 
Fig. 6. Calpain is active in rat but not in human erythrocytes: rat 
and human erythrocytes were hemolysed and the membrane-free ly-
sate (obtained by centrifugation of the lysate at 40000Xg for 30 
min) was resolved by anion exchange chromatography on DEAE-
cellulose to fraction I and fraction II as described [22]. Labeled p53 
was incubated in the presence of the indicated amounts of frac-
tion II protein in the absence or presence of calpastatin purified 
from human erythrocytes (0.15 U; see legend to Fig. 4). Proteolysis 
p53 was monitored as described under Section 2. 
22 H. Gonen et al.lFEBS Letters 406 (1997) 17-22 
native is that the two pathways are involved in different as-
pects of p53 degradation. For example, as has been recently 
suggested [12], calpain may be involved in regulating p53 deg-
radation under basal conditions, whereas the accelerated E6-
dependent process may be mediated by the ubiquitin pathway. 
It should be noted however that Maki and colleagues [5] re-
ported that lactacystin, a highly specific inhibitor of the pro-
teasome (that does not affect calpain activity), inhibits also the 
basal, E6-independent degradation of p53. This result along 
with the energy requirement for p53 degradation [3] and sta-
bilization of the molecule following inactivation of El [4], 
processes that occur in cells that are not transformed by E6, 
leave the question of distinct pathways for E6-dependent and 
-independent degradation of p53 unresolved. 
Interestingly, as can be seen in Fig. 5, some, but not all of 
the substrates of the ubiquitin system are also degraded by 
calpains. These include, in addition to p53, also N-myc, c-Fos, 
and c-Jun. In contrast, lysozyme, that is degraded by the 
ubiquitin system in vitro, is resistant to clapain. There are 
no obvious structural similarities between these substrates. 
In addition, while calpains are proteases, susceptibility to deg-
radation by the ubiquitin system is determined to a large ex-
tent by the ability of the targeted proteins to be recognized by 
specific ubiquitin-protein ligases, E3s, and to be tagged by 
ubiquitin. Thus, it appears that the requirements for recogni-
tion by the two systems are clearly distinct and it is difficult to 
conclude whether the similarity (although as mentioned, not 
identity) in substrate profile between the two systems bears 
also a physiological relevance. 
In conclusion, while one cannot rule out a role for calpains 
in regulating the stability of p53, it appears that a rigorous 
proof for their involvement in the process is still missing and 
that the ubiquitin system plays a major role in the process. 
Similar arguments can be raised also for the involvement of 
the two systems in the degradation of the other mentioned 
transcriptional regulators. 
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